<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141386">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02100683</url>
  </required_header>
  <id_info>
    <org_study_id>TP126</org_study_id>
    <nct_id>NCT02100683</nct_id>
  </id_info>
  <brief_title>Nit-Occlud PDA Post-Approval Study</brief_title>
  <official_title>Nit-Occlud PDA Post-Approval Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PFM Medical, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PFM Medical, Inc</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an FDA post-approval study of the Nit-Occlud PDA Device to evaluate 5 year (60
      months) safety and effectiveness of the device.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Rate of Serious Device and/or Procedure Related Adverse Events as a Measure of Safety</measure>
    <time_frame>5 year (60 months)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The primary safety endpoint is to demonstrate that the 60 months (5 year) serious device and/or procedure related adverse event rate is no worse than the objective performance criterion (OPC) of 1%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Complete PDA Closure as a Measure of Efficacy</measure>
    <time_frame>60 months (5 year)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary effectiveness endpoint is to demonstrate that the 60 month (5 year) complete closure rate for the device is no worse than an OPC of 85%. The closure of the ductus arteriosus will be assessed by absence of residual flow at 60 months (5 years) by transthoracic echocardiogram with 2-D color of color flow mapping and pulse wave Doppler (ECHO).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Device and/or Procedure Related Adverse Events as a Measure of Safety</measure>
    <time_frame>60 months (5 year)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The secondary safety endpoint is to demonstrate that the rate of device and/or procedure related adverse events reported through 60 months (5 years) post procedure is no worse that 6% (OPC rate of 3% plus an added 3% margin).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Echocardiographic Closure as a Measure of Efficacy</measure>
    <time_frame>36 months (3 year)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The secondary effectiveness endpoint is to demonstrate echocardiographic closure at 12 and 36 months is no worse than an OPC of 85%.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">215</enrollment>
  <condition>Patent Ductus Arteriosus (PDA)</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients age 6 months to 21 years weighing &gt; 5kg with an angiographically confirmed PDA
        with a minimum diameter of &lt;4 mm.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Angiographically confirmed PDA with minimum diameter &lt; 4 mm.

          -  Weight is ≥ 5 kg.

          -  Age 6 months to 21 years.

        Exclusion Criteria:

          -  Cardiac anomalies requiring surgery.

          -  Known bleeding or coagulation disorder.

          -  Febrile illness within 7 days of planned procedure.

          -  Pregnancy.

          -  Pulmonary hypertension with increased pulmonary vascular resistance (≥ 5 Wood Units).

          -  Hypersensitivity to contrast medium.

          -  Known nickel allergy.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel S Levi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA Pediatric Cardiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Salvadore Palomares, RAC</last_name>
    <phone>760 758 8749</phone>
    <email>spalomares@pfmmedicalusa.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brent Gordon, MD</last_name>
      <phone>909-558-4207</phone>
      <email>brgordon@llu.edu</email>
    </contact>
    <investigator>
      <last_name>Brent Gordon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Morris M Salem, MD</last_name>
      <phone>323-783-5310</phone>
      <email>morris.m.salem@kp.org</email>
    </contact>
    <investigator>
      <last_name>Morris M Salem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Central California</name>
      <address>
        <city>Madera</city>
        <state>California</state>
        <zip>93636</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carl Owada, MD</last_name>
      <phone>559-353-5476</phone>
      <email>cowada@childrenscentralcal.org</email>
    </contact>
    <investigator>
      <last_name>Carl Owada, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSD Rady Children's Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Moore, MD</last_name>
      <phone>858-966-5855</phone>
      <email>jmoore@rchsd.org</email>
    </contact>
    <investigator>
      <last_name>John Moore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Fagan, MD</last_name>
      <phone>720-777-5682</phone>
      <email>Thomas.Fagan@childrenscolorado.org</email>
    </contact>
    <investigator>
      <last_name>Thomas Fagan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale - New Haven Children's Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeremy Asnes, MD</last_name>
      <email>jeremy.asnes@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Jeremy Asnes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Damien Kenny, MD</last_name>
      <phone>312-942-6880</phone>
      <email>damien_kenny@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Damien Kenny, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ziyad M Hijazi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advocate Christ Medical Center</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexander Javois, MD</last_name>
      <phone>708-684-5580</phone>
      <email>alexander.javois@advocatehealth.com</email>
    </contact>
    <investigator>
      <last_name>Alexander Javois, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dhaval Patel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kentucky Children's Hospital Heart Clinic</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Doug Schneider, MD</last_name>
      <phone>859-323-6754</phone>
      <email>douglas.schneider@uky.edu</email>
    </contact>
    <investigator>
      <last_name>Doug Schneider, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Forbes, MD</last_name>
      <phone>313-745-5835</phone>
      <email>tforbes@dmc.org</email>
    </contact>
    <investigator>
      <last_name>Thomas Forbes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Turner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Srinath Gowda, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ralf Holzer, MD</last_name>
      <phone>614-722-2537</phone>
      <email>ralf.holzer@nationwidechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Ralf Holzer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matt Gillespie, MD</last_name>
      <phone>215-590-1790</phone>
      <email>Gillespie@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Matt Gillespie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vivian Dimas, MD</last_name>
      <phone>214-456-8727</phone>
      <email>vivian.dimas@childrens.com</email>
    </contact>
    <investigator>
      <last_name>Vivian Dimas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Zellers, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alan Nugent, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Suren Reddy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas K Jones, MD</last_name>
      <phone>206-987-2266</phone>
      <email>thomas.jones@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Thomas K Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Agustin Rubio, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Troy Johnston, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Proposed standards for clinical evaluation of patent ductus arteriosus occlusion devices. Multiorganization Advisory Panel to FDA for Pediatric Cardiovascular Devices. Catheter Cardiovasc Interv. 2000 Nov;51(3):293-6. PubMed PMID: 11066109.</citation>
    <PMID>11066109</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 4, 2014</lastchanged_date>
  <firstreceived_date>March 27, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Occluder</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ductus Arteriosus, Patent</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
